AMBI Skincare Fade Cream Recalled for Improper Temperature Storage
AMBI Skincare Fade Cream Oily Skin (2 OZ) is recalled nationwide due to improper storage temperature. The product was stored outside the temperature requirements specified on its label.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall without reported illnesses or injuries. The deviation involves improper product storage temperature, a manufacturing practice issue rather than a confirmed contamination or safety hazard. Recalls involving manufacturing compliance issues without reported harm are classified as moderate severity.
Plain-English summary
AMBI Skincare Fade Cream Oily Skin New & Improved (Net Wt. 2 OZ / 56g) is being recalled by Family Dollar Stores, Llc. The product was stored outside of the temperature requirements specified on its label.
This storage deviation violates current Good Manufacturing Practice (cGMP) standards. The affected product was distributed nationwide.
The recalled product
- Product
- AMBI Skincare Fade Cream Oily Skin New & Improved, Net Wt. 2 OZ (56g)
- Manufacturer
- Family Dollar Stores, Llc.
- Category
- Drug — Skincare
- Hazard
- improper-storage
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- SKUs 2024219
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- ModerateQuality Choice Earwax Removal Kit Carbamide Peroxide Subpotent Drug Recall
FDA (Drugs) · 2026-07-22
- ModerateFamily Wellness Carbamide Peroxide Earwax Removal Kit Subpotent Drug
FDA (Drugs) · 2026-07-22
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22